These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis. Fortenberry YM; Brandal SM; Carpentier G; Hemani M; Pathak AP PLoS One; 2016; 11(10):e0164288. PubMed ID: 27755560 [TBL] [Abstract][Full Text] [Related]
6. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop. Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921 [TBL] [Abstract][Full Text] [Related]
7. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases. Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335 [TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. Allan EH; Martin TJ J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231 [TBL] [Abstract][Full Text] [Related]
9. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1. Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706 [TBL] [Abstract][Full Text] [Related]
10. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Grebenschikov N; Sweep F; Geurts A; Andreasen P; De Witte H; Schousboe S; Heuvel J; Benraad T Int J Cancer; 1999 May; 81(4):598-606. PubMed ID: 10225451 [TBL] [Abstract][Full Text] [Related]
11. A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1. D'Amico S; Martial JA; Struman I FEBS Lett; 2012 Mar; 586(6):686-92. PubMed ID: 22449964 [TBL] [Abstract][Full Text] [Related]
12. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression. Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076 [TBL] [Abstract][Full Text] [Related]
13. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275 [TBL] [Abstract][Full Text] [Related]
14. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886 [TBL] [Abstract][Full Text] [Related]
15. A Conjugate of Two tPA-Binding RNA Aptamers Efficiently Inhibits Fibrinolysis. Bjerregaard N; Dupont DM; Andreasen PA Nucleic Acid Ther; 2017 Apr; 27(2):95-104. PubMed ID: 28051346 [TBL] [Abstract][Full Text] [Related]
16. Localization and distribution of tissue type and urokinase type plasminogen activators and their inhibitors Type 1 and 2 in human and rhesus monkey fetal membranes. Liu YX; Hu ZY; Liu K; Byrne S; Zou RJ; Ny T; d'Lacey C; Ockleford CD Placenta; 1998; 19(2-3):171-80. PubMed ID: 9548184 [TBL] [Abstract][Full Text] [Related]
17. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Brandal S; Blake CM; Sullenger BA; Fortenberry YM Nucleic Acid Ther; 2011 Dec; 21(6):373-81. PubMed ID: 22103403 [TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin. Sorrell AM; Shand JH; Tonner E; Gamberoni M; Accorsi PA; Beattie J; Allan GJ; Flint DJ J Biol Chem; 2006 Apr; 281(16):10883-9. PubMed ID: 16505491 [TBL] [Abstract][Full Text] [Related]
19. The imbalance of plasminogen activators and inhibitor in preeclampsia. Gao M; Nakabayashi M; Sakura M; Takeda Y J Obstet Gynaecol Res; 1996 Feb; 22(1):9-16. PubMed ID: 8624901 [TBL] [Abstract][Full Text] [Related]
20. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]